A
129.90
3.24 (2.56%)
| 前收盘价格 | 126.66 |
| 收盘价格 | 127.70 |
| 成交量 | 381,556 |
| 平均成交量 (3个月) | 623,962 |
| 市值 | 7,762,875,392 |
| 价格/销量 (P/S) | 21.22 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2024 - 11 Nov 2024 |
| 营业毛利率 | -154.12% |
| 营业利益率 (TTM) | -370.18% |
| 稀释每股收益 (EPS TTM) | -9.15 |
| 季度收入增长率 (YOY) | -24.00% |
| 流动比率 (MRQ) | 0.740 |
| 营业现金流 (OCF TTM) | -330.08 M |
| 杠杆自由现金流 (LFCF TTM) | -104.13 M |
| 资产报酬率 (ROA TTM) | -27.92% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Ascendis Pharma A/S | 看跌 | 看涨 |
AIStockmoo 评分
1.8
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.75 |
|
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.73% |
| 机构持股比例 | 104.41% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 207.00 (Stifel, 59.35%) | 购买 |
| 中 | 180.00 (38.57%) | |
| 低 | 153.00 (TD Cowen, 17.78%) | 购买 |
| 平均值 | 179.43 (38.13%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 129.55 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 15 Nov 2024 | 170.00 (30.87%) | 购买 | 126.51 |
| 04 Nov 2024 | 170.00 (30.87%) | 购买 | 125.77 | |
| Oppenheimer | 15 Nov 2024 | 180.00 (38.57%) | 购买 | 126.51 |
| Stifel | 15 Nov 2024 | 207.00 (59.35%) | 购买 | 126.51 |
| TD Cowen | 15 Nov 2024 | 153.00 (17.78%) | 购买 | 126.51 |
| 21 Oct 2024 | 160.00 (23.17%) | 购买 | 128.66 | |
| Wedbush | 15 Nov 2024 | 181.00 (39.34%) | 购买 | 126.51 |
| JP Morgan | 23 Oct 2024 | 174.00 (33.95%) | 购买 | 127.69 |
| B of A Securities | 23 Sep 2024 | 191.00 (47.04%) | 购买 | 146.60 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合